All CTCAE grades for thrombocytopenia, leukopenia, anemia, renal function impairment and xerostomia before and after two cycles of [177Lu]Lu-PSMA-617 RLT with at least one [225Ac]Ac-PSMA-617 augmentation are compiled in Figure 4. Here, FOLH1 is linked to Decreased total leukocyte count.